Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng Yuan

Showing results (1351-1360 of 1,446) with videos related to

Pageof 145
Sort By:
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Open Forum Infectious Diseases|August 5, 2022
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR StudyChen-Hua Liu, Hsin-Yun Sun, Cheng-Yuan Peng, et al.
The Journal of Infectious Diseases|April 9, 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsChung-Feng Huang, Chao-Hung Hung, Pin-Nan Cheng, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Frontiers in Immunology|June 15, 2017
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B PatientsSandra Phillips, Sameer Mistry, Antonio Riva, et al.
The Journal of Clinical Investigation|June 1, 2021
SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infectionTsung-Yu Tsai, Ming-Ting Huang, Pei-Shan Sung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2021
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks PosttreatmentChun Jen Liu, I Shyan Sheen, Chi Yi Chen, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
Pageof 145

Showing results (1351-1360 of 1,446) with videos related to

Sort By:
Pageof 145
Journal of Gastroenterology and Hepatology|November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver DiseaseYun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeksScott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Journal of Medical Virology|January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic FibrosisYu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Open Forum Infectious Diseases|August 5, 2022
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR StudyChen-Hua Liu, Hsin-Yun Sun, Cheng-Yuan Peng, et al.
The Journal of Infectious Diseases|April 9, 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsChung-Feng Huang, Chao-Hung Hung, Pin-Nan Cheng, et al.
Gut|January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver diseaseYu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
Frontiers in Immunology|June 15, 2017
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B PatientsSandra Phillips, Sameer Mistry, Antonio Riva, et al.
The Journal of Clinical Investigation|June 1, 2021
SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infectionTsung-Yu Tsai, Ming-Ting Huang, Pei-Shan Sung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2021
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks PosttreatmentChun Jen Liu, I Shyan Sheen, Chi Yi Chen, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
Pageof 145